Open AccessRelative potency of intravenous oxymorphone compared to other µ opioid agonists in humans — pilot study outcomes
Author(s) -
Shanna Babalonis,
Sandra D. Comer,
Jermaine D. Jones,
Paul A. Nuzzo,
Michelle R. Lofwall,
Jeanne M. Manubay,
Kevin Hatton,
Robert A. Whittington,
Sharon Walsh
Publication year - 2021
Publication title -
psychopharmacology/psychopharmacologia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.378
H-Index - 196
eISSN - 1432-2072
pISSN - 0033-3158
DOI - 10.1007/s00213-021-05872-1
Subject(s) - oxymorphone , hydromorphone , oxycodone , medicine , opioid , morphine , triazolam , placebo , anesthesia , pharmacology , potency , benzodiazepine , chemistry , biochemistry , receptor , alternative medicine , pathology , in vitro
Intravenous (IV) misuse of the µ opioid analgesic oxymorphone has caused significant public health harms; however, no controlled data on its IV abuse potential are available. The primary aims of this pilot study were to directly compare IV oxymorphone to IV oxycodone, morphine, and hydromorphone on a subjective measure of drug liking and to assess relative potency.